Clinical Trial

A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Insulin-naive Subjects With Type 2 Diabetes Mellitus (T2DM)

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated November 28, 2025 (before its estimated August 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study will be conducted to compare the efficacy, safety and patient-reported outcome of once-weekly GZR4 and once-daily Insulin Glargine U100 with Non-Insulin Antidiabetic Agents in Insulin-naive Subjects with Type 2 Diabetes Mellitusin.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-01-05.
Status change: Not Yet Recruiting → Active, Not Recruiting 2025-11-23
Trial Details
NCT Number NCT06767735
Lead Sponsor Gan & Lee Pharmaceuticals.
Conditions Diabetes
Enrollment 580 participants
Start Date 2025-02-17
Primary Completion 2026-08-01 (estimated)
Study Completion 2026-08-17 (estimated)
Updated on ClinicalTrials.gov 2025-11-28